The Latest Biology News And Medical NewsBiology News 2Health News 2Biology News 3Health News 3
HOME >> MEDICINE >> NEWS
ENDEAVOR III Trial reports key findings on new-generation stent

(May 10, 2007ORLANDO, FL) -- New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 912, 2007, in Orlando, FL, will offer clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease.

The Endeavor III trial randomly assigned 436 patients treated at 30 medical centers in the United States to treatment with the investigational Endeavor stent (Medtronic, Minneapolis) or the Cypher stent (Cordis Johnson & Johnson, Miami Lakes, FL). The Endeavor stent is coated with zotarolimus, a medication that, like the Cyphers sirolimus coating, reduces renarrowing of the artery by preventing the growth of scar tissue inside the stent.

Initial data showed that procedural success was higher with the new Endeavor stent, which is more flexible and is considered easier to implant than the Cypher stent. However, at 8 months, the Endeavor stent fell short in angiographic studies, showing significantly greater scar tissue growth, or late loss, in the inner diameter of the artery as compared to the Cypher stent. At 12 months, clinical outcomes were equivalent with the two stents: The combined rates of death, heart attack, and repeat procedures were 8.2 percent in both groups of patients.

At the Orlando SCAI meeting, Martin Leon, M.D., FSCAI, a professor of medicine and associate director of the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York City, will report 2-year clinical outcomes from the Endeavor III trial.

"Long-term follow-up will further clarify not only safety with the zotarolimus-eluting stent but also whether early angiographic disparities translate into differences in late clinical restenosis," he said.

The Endeavor III trial is 1 of 5 studies gathering the data necessary for market approval of the new stent by the Food and Drug Administra
'"/>

Contact: Kathy Boyd David
kbdavid@scai.org
717-422-1181
Society for Cardiovascular Angiography and Interventions
10-May-2007


Page: 1 2

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. NIH names Clinical Trial Units for the Microbicide Trials Network
5. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
6. The Public Library of Science launches the new open access journal PLoS Clinical Trials
7. Trial shows vaccine against cervical cancer provides long-term protection
8. Trial shows malaria vaccine could protect young children from disease for 18 months
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ENDEAVOR III Trial reports key findings new generation stent

(Date:11/24/2009)...MERSET,N.J.,Nov.24/PRNewswire-FirstCall/--TeamStaf...andadministrativestaffingservices,todayannouncedth...ckfromTheNasdaqGlobalMarkettoTheNasdaqCapitalMarke...veattheopeningofbusinessonWednesday,November25,200...erthesymbol"TSTF."TheNasdaqCapitalMarketisacontinu...
(Date:11/24/2009)...STON,Va.,Nov.24/PRNewswire/--LincolnCountyHeathcar...ithtwosmallhospitalsandretirementcommunities,emplo...you,reanITpersonandyou,renotgettingsuccessfulbacku...dentofInformationServicesatLCH.Asisthecasewithmany...tBettsknewheneededabackupredesigntoprotecthismissi...
(Date:11/24/2009)...RRISVILLE,N.C.,Nov.24/PRNewswire/--TheAmericanSoci...ultsofasurveyabouttheimpactofthe2010CMSPhysicianFe...diologistsandcardiovascularultrasoundtechnicianssu...mtostopacceptingMedicarepatients,reducestafforshut...ientaccesstoechocardiography(heartultrasound)andot...
(Date:11/24/2009)...RRYTOWN,N.Y.,Nov.24/PRNewswire-FirstCall/--Regener...spresentationatthe21stAnnualPiperJaffrayHealthcare...isscheduledfor4:00p.m.EasternTime.Thesessionmaybea...om ,ontheInvestorRelationspage.Anarchivedversionof...hroughDecember31,2009.AdditionalinformationaboutRe...
(Date:11/24/2009)...n infancy may lead to persistent wheezing, study f...s) -- Infants exposed to outdoor traffic pollution...thma, researchers say. , Endotoxin -- a compone...nse in humans -- is found in dust. , University...nd persistent wheezing (an early warning sign of a...
Breaking Medicine News(10 mins):Health News:TeamStaff Announces Transfer to Nasdaq Capital Market 2Health News:TeamStaff Announces Transfer to Nasdaq Capital Market 3Health News:Replay 4 Customer Takes Risk, Fights for Budget to Protect Information Systems 2Health News:Lives Compromised and Patient Access Limited with New Cuts to Medicare 2Health News:Traffic, Dust Linked to Asthma in Kids 2
(Date:11/23/2009)...23/PRNewswire-FirstCall/--HealthWarehouse.com,Inc....acy,todayannounceditsfinancialresultsforthethirdqu...erlyrevenueof$1,006,721,drivenbyheavygrowthinpresc...ased13.0%year-over-yearto34.6%andthenetlossfortheq...ethreemonthsendedSeptember30,2008. ,, "Wecontin...
(Date:11/23/2009)...PRNewswire/--TwooftheChicagoarea,sleadingBoardCert...women,sbreastimaging,couplingthelatesttechnologyin...undwiththeabilitytohavethefullrangeofdigitalimagin...resheleavestheoffice.Drs.AhmedFaragandJoanWerberar...current6-9monthwaitforanappointmentcommonlyfoundin...
(Date:11/23/2009).../PRNewswire-FirstCall/--NuVasive, Inc. (Nasdaq: NU...ctsforminimallydisruptivesurgicaltreatmentsforthes...efExecutiveOfficer,andMichaelJ.Lambert,ExecutiveVi...presentatthe21stAnnualPiperJaffrayHealthCareConfer...y,December2,2009,at10:00a.m.ET.Mr.LukianovandMr.La...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 3NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 2NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 3Can an over the counter vitamin like substance slow the progression of Parkinsons disease 3F 10003 1Can an over the counter vitamin like substance slow the progression of Parkinsons disease 3F 10003 2Regence BlueShield Receives Top Marks in Insurance Survey 57837 1Regence BlueShield Receives Top Marks in Insurance Survey 57837 2News from the Latest Issue of Molecular Medicine 57834 1News from the Latest Issue of Molecular Medicine 57834 2
Other News:
...Georgetown University's Lombardi Comprehensive Can...that allows thousands of tumor slices to be screen...ore expensive methods that can analyze only severa...ate that this technology could someday lead to mor...
...o the 4 percent of Americans with potentially life...t food, often nuts or shellfish. But that may chan...onsortium, announced today, strive to develop ther...consortium, led by Hugh Sampson, M.D., at the Moun...
... drug can survive an otherwise lethal dose of vacc...cientists supported by the National Institute of A...e National Institutes of Health. The findings, say...r drugs might be useful in preventing adverse side...
...logist reports, for the first time in a large pros...rectile dysfunction (ED) and heart problems can no... men restore function and quality of life.......Dr...inEngland dedicated to providing sexual advice to ...
health news:Georgetown cancer researchers develop high throughput method 2health news:New food allergy research consortium focuses on peanut allergy 2health news:New food allergy research consortium focuses on peanut allergy 3health news:Cancer drug slows poxvirus in mice 2health news:Vascular disease most common cause of male erectile dysfunction 2
...efs and attitudes towards patients with chronic fa...ment, finds new research available on bmj.com........6 general practitioners in England, based on a ser...chronic fatigue syndrome or irritable bowel syndro...
...xplained infant deaths have led to widespread conf...to take part in child protection cases, warn exper...t review of procedures to restore faith in the chi...ndrome by proxy received publicity when in 1977 Me...
...over 130,000 older people in this week's issue of ...xygenase-2 (COX-2) inhibitor celecoxib may have a ...th other non-steroidal anti-inflammatory drugs. ..... drugs (NSAIDs) are commonly used by older people ...
...onal Institute of Allergy and Infectious Diseases ..., have conducted studies in mice to gain a new pic...re prompted to destroy infected cells. Their insig...cines that induce desired T-cell responses.......T...
health news:Mouse study could aid vaccine designers 2